Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the European Patent Office (“EPO”) has granted a patent for AV-101, Vistagen’s oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist. “Expanding our patent portfolio for all of our product candidates is an ongoing priority to support our global development and commercialization strategies across our pipeline,” said Shawn Singh, chief executive officer of Vistagen. “AV-101’s potential to inhibit the function of the NMDAR, without fully blocking it like other NMDAR antagonists such as ketamine, anchors our interest in developing it as an innovative therapy for millions of patients affected by CNS disorders involving the NMDAR. This new patent covering our improved and streamlined manufacturing process may result in advantages for getting AV-101 to patients, on our own or potentially with a partner.”
To view the full press release, visit https://ibn.fm/GJ8gl
About VistaGen Therapeutics Inc.
Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster-acting and with fewer side effects and safety concerns than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes multiple product candidates, including fasedienol and itruvone, belonging to a new class of drugs known as pherines, in addition to an oral NMDAR antagonist. Pherines, which are administered as nasal sprays, are designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. For more information, visit the company’s website at www.Vistagen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork